Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$155.17 USD
-0.33 (-0.21%)
Updated Nov 22, 2024 04:00 PM ET
After-Market: $155.35 +0.18 (0.12%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
JNJ 155.17 -0.33(-0.21%)
Will JNJ be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for JNJ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for JNJ
Pharma Stock Roundup: EU Nod for PFE's Hympavzi, NVS Ups Sales View
Merck Stock Trades Near 52-Week Low: What's Next for Investors?
JNJ: What are Zacks experts saying now?
Zacks Private Portfolio Services
J&J Loses Around $24B in a Month: How to Play the Stock?
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLC
Other News for JNJ
Sanofi becomes latest drugmaker to challenge HHS over 340B drug-discount program
Sanofi planning changes to 340B hospital drug discount plan, WSJ reports
Sanofi planning changes to 340B hospital drug discount plan, WSJ reports
Trump picks surgeon Marty Makary to head FDA, Rep. Dave Weldon to lead CDC
Johnson & Johnson seeks FDA approval for its ulcerative colitis treatment